2025 Annual Meeting | S11 - Pain
| 11:15 AM - 11:17 AM PDT | Speaker |
2025 Mitchell B. Max Award for Neuropathic Pain: This award recognizes an individual for outstanding work in the field of neuropathic pain
Brian Callaghan, MD, MS, FAAN |
| 11:27 AM - 11:39 AM PDT | Abstract |
002 - Suzetrigine, a Selective Pain Signal Inhibitor of NaV1.8 Shows Proof-of-concept for Treatment of Painful Diabetic Peripheral Neuropathy
Roy L. Freeman, MD |
| 11:39 AM - 11:51 AM PDT | Abstract |
003 - The Interplay of Sympathetic Hyperactivity and Small Fiber Damage in Fibromyalgia Patients
Pietro Falco, MD |
| 11:51 AM - 12:03 PM PDT | Abstract |
004 - Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-class TRPM3 Antagonist for Pain and Migraine
Volkan Granit, MD |
| 12:03 PM - 12:15 PM PDT | Abstract |
005 - Vascular Compression in Trigeminal Neuralgia Discloses Trigeminal Root Somatotopic Organization
Gianfranco De Stefano |
| Nathaniel M. Schuster, MD | Dr. Schuster has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Schedule 1 Therapeutics. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Averitas. Dr. Schuster has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Syneos. Dr. Schuster has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lohocla Research Corporation. Dr. Schuster has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Vertex. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapport Therapeutics. Dr. Schuster has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eli Lilly & Co. Dr. Schuster has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Averitas. Dr. Schuster has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Pain Medicine Journal. Dr. Schuster has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for Various Law Firms and the State of California. The institution of Dr. Schuster has received research support from Migraine Research Foundation. The institution of Dr. Schuster has received research support from UCSD Academic Senate. The institution of Dr. Schuster has received research support from NINDS 1 R01 AT012048-01A1. The institution of Dr. Schuster has received research support from NCCIH 5R00AT009466-04. The institution of Dr. Schuster has received research support from NCCIH U24 NS115714. The institution of Dr. Schuster has received research support from NIH/HEAL EN21-01. |
| Barbara P. Karp, MD, FAAN | Dr. Karp has received personal compensation in the range of $500-$4,999 for serving as a Faculty for a course on chemodenervation with Catalyst Medical 好色先生. |
| Brian Callaghan, MD, MS, FAAN | Dr. Callaghan has received personal compensation for serving as an employee of University of Michigan. Dr. Callaghan has received personal compensation for serving as an employee of Ann Arbor Veterans Affairs. Dr. Callaghan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dynamed. Dr. Callaghan has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生. Dr. Callaghan has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Medico-legal work. Dr. Callaghan has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Vaccine Injury Compensation Program. The institution of Dr. Callaghan has received research support from 好色先生. The institution of Dr. Callaghan has received research support from JDRF. The institution of Dr. Callaghan has received research support from NIA. Dr. Callaghan has received personal compensation in the range of $500-$4,999 for serving as a Grant Reviewer with NIH. |
| Pietro Falco, MD | Dr. Falco has nothing to disclose. |
| Eleonora Galosi | Eleonora Galosi has nothing to disclose. |
| Giuseppe Di Pietro | Mr. Di Pietro has nothing to disclose. |
| Gianfranco De Stefano | Mr. De Stefano has nothing to disclose. |
| Caterina Leone | Caterina Leone has nothing to disclose. |
| Giulia Di Stefano | Giulia Di Stefano has nothing to disclose. |
| Andrea Truini | No disclosure on file |
| Volkan Granit, MD | Dr. Granit has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Granit has stock in Biohaven. Dr. Granit has received personal compensation in the range of $10,000-$49,999 for serving as a Faculty Member with University of Miami. |
| Richard Bertz | Richard Bertz has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Richard Bertz has stock in Biohaven Pharmaceuticals. |
| Andrew Lucas, PharmD, MS, MS | Dr. Lucas has nothing to disclose. |
| Mary Donohue | Mary Donohue has received personal compensation for serving as an employee of Biohaven Pharmaceuticals, Inc.. Mary Donohue has stock in Biohaven Pharmaceuticals, Inc.. |
| Patricia Mydlow | Patricia Mydlow has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Biohaven Pharma. |
| Beth Emerson, MD | Dr. Emerson has received personal compensation for serving as an employee of Biohaven. Dr. Emerson has received personal compensation for serving as an employee of Pfizer. Dr. Emerson has stock in Biohaven. Dr. Emerson has stock in Pfizer. |
| Christopher Jensen, PharmD | Dr. Jensen has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Jensen has stock in Biohaven Pharmaceuticals. |
| Eric Ashbrenner | Eric Ashbrenner has received personal compensation for serving as an employee of Biohaven. Eric Ashbrenner has stock in Biohaven. An immediate family member of Eric Ashbrenner has stock in Biohaven. |
| Joris Vriens | Joris Vriens has received intellectual property interests from a discovery or technology relating to health care. |
| Thomas Voets | Thomas Voets has received intellectual property interests from a discovery or technology relating to health care. |
| Irfan Qureshi, MD | Dr. Qureshi has received personal compensation for serving as an employee of Biohaven. Dr. Qureshi has stock in Biohaven Pharmaceuticals. |
| Vladimir Coric | Vladimir Coric has received personal compensation for serving as an employee of Biohaven. Vladimir Coric has received personal compensation in the range of $1,000,000+ for serving as an officer or member of the Board of Directors for Bioahven. Vladimir Coric has stock in Biohaven. Vladimir Coric has received intellectual property interests from a discovery or technology relating to health care. |
| Emanuele Ripiccini, PhD | Dr. Ripiccini has nothing to disclose. |
| Daniel Litewczuk | Daniel Litewczuk has nothing to disclose. |
| Roy L. Freeman, MD | Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. |
| Richard Rauck, MD | Dr. Rauck has nothing to disclose. |
| Charles E. Argoff, MD | Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nevro. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for XGene. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vertex. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scilex. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Colllegium. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Argoff has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Allergan/Abbvie. Dr. Argoff has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Lundbeck. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Scilex. Dr. Argoff has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Scilex. The institution of Dr. Argoff has received research support from Lilly. The institution of Dr. Argoff has received research support from Lundbeck. The institution of Dr. Argoff has received research support from Abbvie. The institution of Dr. Argoff has received research support from Vertex. Dr. Argoff has received publishing royalties from a publication relating to health care. |
| Simon Tian, MD | Dr. Tian has nothing to disclose. |
| Xiaopeng Miao, PhD | Dr. Miao has received personal compensation for serving as an employee of Vertex Pharmaceulticals. Dr. Miao has stock in Vertex Pharmaceulticals. Dr. Miao has stock in Biogen . |
| Hannah Bouldin Olivet, MD | Dr. Bouldin Olivet has received personal compensation for serving as an employee of Vertex. Dr. Bouldin Olivet has stock in Vertex. |
| Carmen Bozic, MD | Dr. Bozic has received personal compensation for serving as an employee of Vertex Pharmaceuticals. Dr. Bozic has stock in Vertex Pharmaceuticals. |
| Robert H. Dworkin, PhD | Robert H. Dworkin, PhD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia, Akigai, Allay, AM-Pharma, Analgesic Solutions, Beckley, Biogen, Biosplice, Bsense, Cardialen, Chiesi, Clexio, Collegium, CombiGene, Confo, Contineum, Eccogene, Editas, Eli Lilly, Emmes, Endo, Epizon, Exicure, GlaxoSmithKline, Glenmark, Gloriana, JucaBio, Kriya, Mainstay, Merck, Mind Medicine, NeuroBo, Noema, OliPass, Orion, Oxford Cannabinoid Technologies, Pfizer, Q-State, Regenacy, Rho, Sangamo, Semnur, SIMR Biotech, Sinfonia, SK Biopharmaceuticals, Sparian, SPM Therapeutics, SPRIM Health, Tiefenbacher, Validae, Vertex, Viscera, and WCG. |